Search PubMed⌕ Search

Biomedical subjects

M Oda

Publications and source records attributed to M Oda.

At least 523 records · Page 29Linked to original sources
PubMed1985

[Damage to the heart from tumor irradiation in the thorax--an echocardiographic study].

The authors give a review of 74 patients with radiation-induced heart disease which could be easily detected by echocardiography. In almost all of the patients a pericardial effusion (P.E.), with relative sinus tachycardia was found 3 to 4 weeks after onset of radiation and this was transient in some cases. This phenomenon was interpreted as an early radiation-induced reaction of the heart. 6 to 12 months after radiation, late damage of the heart occurred depending on field and total radiation dose. This manifested as massive P.E. with changes in ECG. Later there was damage to the myocardium caused by coronary sclerosis. The tendency to constrictive pericarditis was manifested not earlier than 3 years or later after radiation. The authors advise follow up of the irradiated patients case by case, checked by echocardiography, especially those who received more than 5000 rad to the heart area and therefore have high risk of late heart damage.

Aged↗
PubMed1984

Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor.

A new type of neutral lipid, 1-O-alkyl-2-acetyl-sn-glycerol (AAG), induced a delayed aggregation pattern on interaction with washed rabbit platelets. Although far less potent on a molar basis than platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, AGEPC, nevertheless this compound caused an aggregation, albeit delayed in time, remarkably similar to that exhibited by AGEPC. In view of the possible formation of AGEPC in this reaction, AAG was incubated with washed rabbit platelets, and a lipid corresponding in chromatographic behavior to AGEPC was isolated and identified as such by a combined gas-liquid chromatography/mass spectrometry technique coupled with selected ion monitoring.

Animals↗
PubMed1984

Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice.

Protective activities of the filamentous hemagglutinin (FHA) and the lymphocytosis-promoting factor (LPF) of Bordetella pertussis were compared by active and passive protection tests with intracerebral or respiratory challenge in mice. Mice immunized twice by intraperitoneal injection of 8 micrograms of FHA or glutaraldehyde-inactivated LPF were protected after aerosol challenge. One intraperitoneal injection of inactivated LPF also protected mice from intracerebral challenge; the dose protecting 50% of the mice was 8.5 micrograms. However, one intraperitoneal injection of 48 micrograms of FHA or two weekly intraperitoneal injections of 20 micrograms did not protect mice from death after intracerebral challenge. Injection of affinity-purified antibody to LPF from mouse hybridomas or from goats gave a dose-dependent protection against aerosol challenge. The smallest dose giving protection was 80-90 micrograms. Polyclonal or monoclonal antibody to FHA at doses of 1,440 micrograms or 360 micrograms, respectively, gave very little protection from disease after respiratory challenge. These data indicate that active immunization of mice followed by respiratory challenge with B. pertussis is a useful model to identify protective antigens.

Animals↗
PubMed1984

Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.

FUT-175, 6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulfonate (nafamstat mesilate), a novel synthetic protease-inhibiting agent, was studied to determine its in vitro effects against various proteases and other enzymes, as well as to determine its in vivo protease inhibitory effects. FUT-175 was found to inhibit, in an intense, specific and reversible way, the enzyme activities of trypsin, C1r, C1s, thrombin, kallikrein and plasmin with IC50 values of the order of 10(-6)-10(-8) M. FUT-175 also inhibited complement-mediated hemolysis, including both classical and alternative pathways, sites of inhibition being on C1r and C1s as evidenced by the intermediate-cell technique. In animal model reactions in which the complement system is known to be involved as pathogenetic factors, e.g., Forssman shock, Forssman cutaneous vasculitis, zymosan-induced paw edema, endotoxin shock and local Shwartzman reaction, FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock. FUT-175 was also found to be effective in trypsin-induced shock in mice, in lethality due to thrombin-thrombosis in mice and in kinin formation in the inflammatory process in rats.

Animals↗
PubMed1984

Effect of extracorporeally induced total body hyperthermia for cancer on cardiovascular function.

Total body hyperthermia (TBHT) was induced in patients with terminal cancer, using a femoral arterio-venous shunt as an extracorporeal circuit incorporating a heat exchanger. A total of 31 systemic hyperthermic treatments lasting 3 to 4 hours at 41.5 degrees C to 42 degrees C (rectal temperature) were performed on 11 patients; chemotherapy had previously been unsuccessful in all of these cases. The effect of TBHT on cardiovascular function was explored in these patients. The heart rate and cardiac output were always markedly increased during hyperthermia, however, the peripheral arterial, central venous, pulmonary arterial and pulmonary wedge pressures were little affected and no progressive metabolic acidosis occurred. TBHT was generally well tolerated and there was no instance in which this treatment had to be terminated because of severe cardiovascular failure during hyperthermia.

Adult↗
PubMed1984

[Indications of extracorporeal surgery (autotransplantation) for upper urinary tumors and renal calculi].

Renal preservation and cure of bilateral occurrence of renal tumors or stones as well as occurrence in solitary kidney put all urologists on the thorns of dilemma. Application of extracorporeal surgery resulting in autotransplantation of the kidney for such complicated cases seems useful. Case 1 was a bilateral renal Wilms' tumors in a 17-month-old boy, case 2 and 3 were undiagnosed tumors in renal pelvis and ureter. Extracorporeal surgery enables an accurate partial nephrectomy and yet helps to avoid not only the dissemination of tumor cells, but also undesired nephrectomy in case of benign origin. On the contrary, bilateral nephrectomy followed by dialysis or homo-transplantation will result in an immunosuppressive state and the radicality may only be temporary. Besides, the 5-year survival of dialysis therapy is in the range of 60-65%. Thus the indication of autotransplantation was signified in the tumor situation of case 1. For the 2nd and 3rd cases, this method seems to be the best in satisfying the dilemma in discussion. Likewise, the complicated renal calculi could be completely removed without further deterioration of renal function if they were extracorporeally treated and autotransplanted. We proved that 83% of the difficult stones can be completely removed under hypothermia in situ. For application of autotransplantation to the calculous disease, we feel observation of contraindication is essential for better results at this stage.

Adult↗
PubMed1984

[Combination chemotherapy with neocarzinostatin(NCS), HCFU and picibanil(NHO therapy) for advanced carcinoma of the digestive system--a comparative study with NF, and NFO therapy].

We have previously reported the clinical effects of NF therapy (NCS + 5-FU) and NFO therapy (NCS + 5-FU + Picibanil) on patients with advanced carcinoma of the digestive organs. In the present study, (NHO therapy (NCS + HCFU + Picibanil) performed in 41 patients and 30 patients were evaluated for its clinical effects. In comparison with NHO, NF and NFO, partial regression (tumor regression exceeding 50%) was noted in 5 of 30 patients (16.7%) on NHO, which was superior to 7.4% on NF, but slightly inferior to 18.8% on NFO. However, six and twelve month survival rate and 50% survival month on NHO therapy were 31.6%, 10.5% and 4.6 months, respectively and they were superior to those of NF and NFO therapy. Though the incidence of the adverse effects by NHO was almost identical with that of NFO and not more frequent than that of NF therapy. Urinary frequency, hot sensation and urgency due to HCFU administration were observed approximately in 10% on NFO therapy. In the three modalities the advantageous clinical effects on patients with hepatic carcinoma irrespective of primary or metastatic were observed.

Adult↗
PubMed1984

[Pharmacological studies of FUT-175, nafamstat mesilate. III. Anti-inflammatory activities of FUT-175].

Anti-inflammatory effects of FUT-175 (nafamstat mesilate), a new synthetic serine protease inhibitor, on various types of experimental inflammation were investigated in vivo and in vitro, in comparison with non-steroidal anti-inflammatory drugs (NSAID). The in vivo studies showed that FUT-175 has the abilities to inhibit almost all types of inflammatory reactions employed in the present study. In particular, being evaluated on the basis of the effect of indomethacin, FUT-175 exhibited relatively higher potencies against some reactions such as zymosan-induced increase of vascular permeability, scald paw edema, zymosan-induced granuloma-pouch, the Arthus reaction and acetic acid-induced writhing in which the complement system or the kallikrein-kinin system are considered to play an important role. The in vitro studies showed that FUT-175 is quite different from NSAID, that is, FUT-175 had no effects on heat-induced erythrocyte-lysis and heat-induced denaturation of bovine serum albumin. FUT-175 also had no effect on chemotaxis of polymorphonuclear leucocytes, but inhibited the production of chemotactic factor by antigen-antibody reaction. These above results suggested that FUT-175 has a different mode of action from NSAID and that serine protease inhibiting activities of this compound might play an important role in its anti-inflammatory effect.

Animals↗
PubMed1984

Laparoscopic ultrasonography. Diagnosis of liver and pancreatic cancer.

We tested two kinds of laparoscopic ultrasonography having a 3.5 MHz and a 5.0 MHz, linear assay, generated into 45-mm-long and 13-mm-wide laparoscopic tip. Twenty studies were performed in 6 patients with HCC, 2 patients with pancreatic cancer and others. It is clearly demonstrated that this apparatus provides sufficient resolution real-time ultrasound visualization of a target organ on which ultrasonic probe is placed under direct vision.

Carcinoma, Hepatocellular↗
PubMed1984

[Serum levels of mitomycin C following a high-dose continuous hyperthermic peritoneal perfusion].

Valid therapeutic means have not been established for treatment of disseminated peritoneal metastasis of carcinoma. Continuous hyperthermic peritoneal perfusion (CHPP) with high-dose of mitomycin-C (MMC) was applied to 26 patients with peritoneal metastasis from gastric, rectal or ovarian cancers. Levels of MMC in the sera and in the perfusate were measured. The results obtained were: 1. Approximately a half of the dose of MMC added into the perfusion fluid was recovered. 2. When perfused with 100 mg of MMC, the maximum serum concentration of MMC was equivalent to 1/3 of the maximum serum level when injected with 10 mg of MMC intravenously. Therefore, MMC which could not be detected in CHPP seemed to be retained in the abdominal cavity. 3. Bone marrow inhibition caused by CHPP was observed in only 2 of 26 patients. 4. The total dose of 300 mg of MMC, consisting of the maximum dose of 100 mg each, is acceptable in CHPP without any severe side effect. 5. CHPP exerts antitumor effects when utilizing hyperthermia and a high-dose of MMC on the disseminated peritoneal foci of carcinoma.

Female↗
PubMed1984

[Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer].

To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0.8-1.0 mg/kg/week) combined with 5-FU (250 mg/body/day) was performed for 10 patients with primary or metastatic hepatic cancer. As the results, partial response was obtained in 6 of 8 evaluable patients. However, the adverse effect was very high rate; leucopenia, thrombocytopenia and vomiting (nausea) were observed in 9, 6 and 6 of 10 patients respectively. The dose limiting factor of CDDP was not a nephrotoxicity but a bone marrow depression in this series. Though a noticeable antitumor effect of this modality was obtained, some improvements should be applied to it to decrease the adverse effect.

Adult↗